ClinicalTrials.gg
RecruitingNCT06247267Updated Jul 29, 2025

The Effect of Sex Steroid Replacement Therapy in the Hypogonadism and Transgender Active-Duty Population

An observational study in Hypogonadism and Gender Identity Dysphoria, sponsored by Walter Reed National Military Medical Center. Recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-29.

Sponsored by Walter Reed National Military Medical Center · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2025, 1 year 3 months ago, but the record still lists the study as recruiting.
  • Started Mar 2021; still recruiting 5 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
75
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 185 studies in Hypogonadism with a site in United States — 12 open to participants now, 15 under way, 2 of them phase 3. Hypogonadism · United States.

Planned enrollment
13th of 27
75 · median 70
Started
2021
with 6 others
Observational
28 of 185
4 open now
Primary completion
2025-08
later than 2 of 13 live
Registered
173rd of 185
by date

Among the 185 studies in Hypogonadism with a site in United States, this one is the 13th largest by planned enrollment of the 27 observational ones that give a count, is one of 7 that started in 2021, is one of 28 observational ones, reaches primary completion later than 2 of the 13 other live ones, and was the 173rd registered.

Hypogonadism

320 studies on the registry are indexed under Hypogonadism; 39 are open to participants now.

Browse Hypogonadism studies →

Open to participants now

12 of the 185 studies in Hypogonadism with a site in United States are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 24 Hypogonadism studies recruiting now, 9 (38%) set no upper age limit and 12 (50%) stop at 75 or younger; 6 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 185 studies in Hypogonadism with a site in United States, or all of them as a file.
02

Study summary

It has been known that both estrogen and testosterone are the major sex steroids regulating bone metabolism and other physiological changes in both male and female, respectively. In postmenopausal women, osteoporosis is a major concern secondary to the lack of estrogen. These patients also experience a number of physiological changes that affect their life permanently to include hot flashes, irritability, difficulty concentrating, depression and mental confusion. In hypogonadal men, testosterone deficiency could lead to higher prevalence of depression, osteoporosis, fracture and frailty. Given the new military policy starting to support treatment for gender identity dysphoria military personnel, the number of transgender patients in our Endocrinology clinic has been slowly increasing over the past several months. These patients will require either testosterone replacement therapy or estrogen therapy to achieve their desired sexual characteristics. However, as mentioned above, the lack of estrogen or testosterone in female and male, respectively, could cause several issue in their body composition, cognitive function and quality of life. We designed this prospective case-control study to include patients with hypogonadism and the transgendered populations to learn about the long-term effects of these hormonal replacement therapies on bone density, fractures, memory/cognitive function and quality of life. This is a repetitive measures study taken at baseline, 6-months, and 12-months for three groups consisting of at least 75 subjects. The study will involve 3 arms, i.e. Group 1 primary/secondary untreated hypogonadism, Group 2 male-to female (MTF), and Group 3 female-to-male (FTM) participants that are planning to start hormone replacement therapy as per standard clinical guidelines.

Read the detailed description

The Endocrine Society defines male hypogonadism as a clinical syndrome that results from failure of the testis to produce physiological levels of testosterone (androgen deficiency) and the normal number of spermatozoa caused by disruption of one or more levels of the hypothalamic-pituitary-gonadal (HPG) axis. It is characterized by low serum testosterone/ high LH/high FSH concentrations (primary hypogonadism) or low testosterone/low LH/low FSH (secondary hypogonadism). The main constellation of signs and symptoms may include erectile dysfunction , decreased libido and volume of ejaculation, decreased lean body mass with increased body fat, loss of body and facial hair, weakness, fatigue, anemia and decreased bone density. There is only little data from large cross-sectional studies that address the impact of hypogonadism on morbidity. However, some small studies have concluded that testosterone deficiency could lead to a higher prevalence of depression, osteoporosis, fracture and frailty . Hypogonadism defined as serum total testosterone level \<300 ng/dl has been shown to be related to decreased bone mineral density (BMD). Further review of the literature found various epidemiological studies in men that showed the associations between testosterone and estradiol levels and BMD. They found that estrogen has a major role in regulating bone resorption but both estrogen and testosterone play a role in maintaining bone formation. A recent published trial in 2017 also showed that testosterone replacement therapy in older men was associated with significant greater improvements in stair-climbing power, muscle mass and power. Similar studies found that deficiency of testosterone would lead to decrease in lean mass, muscle size and strength. Given that these two sex steroid hormones, testosterone and estrogen, play an important role in men and women, respectively, we also study their long-term effects in the transgender population once they were started on the opposite gender hormone and lack of their own endogenous production.

03

Conditions studied

  • Hypogonadism
  • Gender Identity Dysphoria

Keywords

  • Transgender
  • Gender dysphoria
  • Hypogonadism
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The study findings will be generalized to patients ages of 18 to 65 who are planning to be placed on sex steroid hormone either for hypogonadism or transgender treatment as per clinical guidelines.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female DoD health care beneficiaries
  • Ages 18-65
  • Diagnosed with primary hypogonadism or transgender treatment for at least 6 months
  • Under care for gender identity dysphoria
  • On stable dose of sex hormonal therapy for at least 6 months prior to enrolling
  • Must be living in the Washington, D.C. area for at least 12 months following enrollment

Exclusion criteria

Exclusion Criteria:

  • Pregnancy, plan for pregnancy in the next 12 months
  • Cardiac disease, especially coronary artery disease
  • Malabsorption disorder
  • Gastrointestinal surgeries
  • Significant renal or liver dysfunction
  • Seizure disorders
  • recent orders to move out of the geographic area
  • Age less than 18 years old or older than 65 years old
  • Scheduled for deployment
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
75 participants (estimated)
Patient registry
No

Groups and cohorts

  • Primary/Secondary Untreated Hypogonadism

    Subjects in group 1 will take clinically indicated testosterone replacement therapy (Fortesta-injection, gel and transdermal) for 12 months with titration for a serum total T level between 300-600 ng/dL.

    Drug: Fortesta

  • Male-to-Female (MTF)

    Subjects in group 2 will take clinically indicated estrogen therapy (Estradiol-orally and transdermal and/or spironolactone-orally) for 12 months for hormonal transition period.

    Drug: Estradiol

  • Female-to-Male (FTM)

    Subjects in group 3 will take clinically indicated testoserone replacement therapy (Fortesta-injection, gel and transdermal) for 12 months for hormonal transition period.

    Drug: Fortesta

Interventions

  • DrugTestosteroneStudies of TestosteroneTestosterone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Primary/secondary untreated hypogonadism patients receive Fortesta injection, gel and transdermal treatment for 12 months with titration for a serum total T level between 300-600ng/dL.

  • Male-to-female (MTF) receive Estradiol orally and transdermal and/or spironolactone-orally) treatment for 12 months for hormonal transition period.

  • DrugTestosteroneStudies of TestosteroneTestosterone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Female-to-male (FTM) receive Fortesta injection, gel and transdermal treatment for 12 months for hormonal transition period.

06

What researchers measure

Primary outcomes

  1. Effects of sex steroid hormone replacement therapy on body composition

    Subjects will undergo Dual energy X-ray Absorptiometry conducted by the research coordinator assessing bone density, body composition, and risk of fractures.

    Time frame: 12 months

  2. Effects of sex steroid hormone replacement therapy in treating hypogonadism and in transgender patients using Dual energy X-ray Absorptiometry assessing body composition and Bone Mineral Density

    We designed this prospective case-control study to include patients with hypogonadism and the transgendered populations to learn about the long-term effects of these hormonal replacement therapies on bone density, fractures, memory/cognitive function and quality of life. This is a repetitive measures study taken at baseline, 6-months, and 12-months for three groups consisting of at least 75 subjects. The study will involve 3 arms, i.e. Group 1 primary/secondary untreated hypogonadism, Group 2 male-to female (MTF), and Group 3 female-to-male (FTM) participants that are planning to start hormone replacement therapy as per standard clinical guidelines.

    Time frame: 12 months

Secondary outcomes

  1. Examination and comparison of the general health questionnaire among the three study groups

    Subjects will undergo a quality of life general health assessment conducted by study investigators

    Time frame: 12 months

Other outcomes

  1. Examination and comparison of the Beck Depression Inventory (a 21-item self-reporting questionnaire for evaluating the severity of depression in normal and psychiatric populations) among the three study groups

    Subjects will undergo the Beck Depression Inventory conducted by study investigators. Scores of 0-9: indicates minimal depression 10-18: indicates mild depression 19-29: indicates moderate depression 30-63: indicates severe depression. Higher total scores indicate more severe depressive symptoms. Some items on the BDI have more than one statement marked with the same score.

    Time frame: 12 months

  2. Examination and comparison of the Wechsler Memory Scale (a comprehensive tool for assessing verbal, visual, working, and recognition memory)

    Subjects will undergo the Wechsler memory scale conducted by study investigators. The Wechsler Memory Scale is an individually administered battery designed to assess various memory and working memory abilities of individuals (e.g. auditory memory, visual memory, visual working memory, immediate memory, delayed memory.

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2021 (actual). Primary completion is estimated for Aug 2025, 53 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 26, 2023
First posted
Feb 7, 2024
StartActual
Mar 9, 2021
Primary completionEst.
Aug 2025
CompletionEst.
Aug 2025
Last update
Jul 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06247267
Lead sponsor
Walter Reed National Military Medical Center
Responsible party
Thanh Hoang (Principal Investigator, Walter Reed National Military Medical Center) — Principal investigator
First posted
Feb 7, 2024
Start date
Mar 9, 2021
Primary completion
Aug 2025 (estimated)
Completion
Aug 2025 (estimated)
Last update
Jul 29, 2025

Study contacts

CAPT Than D Hoang, D.O., MC, USN
Contact
thanh.d.hoang.mil@health.mil
301-295-5165
Iris E Morris, BA
Contact
iris.e.morris3.civ@health.mil
301-319-4599
Thanh D Hoang, MD
principal investigator · Walter Reed National Military Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion